SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis.
Saved in:
| Title: | SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis. |
|---|---|
| Authors: | Neuen BL; The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.; Department of Renal Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia., Fletcher RA; The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.; Department of Public Health and Primary Care, British Heart Foundation Cardiovascular Epidemiology Unit and Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge, United Kingdom., Anker SD; Department of Cardiology (CVK) of German Heart Center Charité, Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin, Berlin, Germany., Bhatt DL; Mount Sinai Heart, New York, New York., Butler J; Baylor Scott and White Research Institute, Temple, Texas., Cherney DZI; Toronto General Research Institute, University Health Network, University of Toronto, Toronto, Ontario, Canada., Docherty KF; School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom., Inzucchi SE; Yale University School of Medicine, New Haven, Connecticut., Jardine MJ; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., Mahaffey KW; Stanford Center for Clinical Research, Department of Medicine, Stanford University, Stanford, California., McCausland FR; Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., McGuire DK; University of Texas Southwestern Medical Center, Dallas., McMurray JJV; School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom., Neal B; The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.; Imperial College London, London, United Kingdom., Packer M; Imperial College London, London, United Kingdom.; Baylor University Medical Center, Dallas, Texas., Patel SM; TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Perkovic V; The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia., Sabatine MS; TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Sardell RJ; Renal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health (NDPH), University of Oxford, Oxford, United Kingdom., Solomon SD; Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Vaduganathan M; Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Wanner C; Renal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health (NDPH), University of Oxford, Oxford, United Kingdom.; University Hospital of Würzburg, Würzburg, Germany., Wheeler DC; Department of Renal Medicine, University College London, London, United Kingdom., Zannad F; Université de Lorraine, Inserm and CHRU de Nancy, Vandœuvre-lès-Nancy, France., Haynes R; Renal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health (NDPH), University of Oxford, Oxford, United Kingdom.; Oxford Kidney Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom., Staplin N; Renal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health (NDPH), University of Oxford, Oxford, United Kingdom., Herrington WG; Renal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health (NDPH), University of Oxford, Oxford, United Kingdom.; Oxford Kidney Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom., Heerspink HJL; The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, the Netherlands. |
| Corporate Authors: | SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium (SMART-C) |
| Source: | JAMA [JAMA] 2026 Jan 20; Vol. 335 (3), pp. 233-244. |
| Publication Type: | Journal Article; Meta-Analysis |
| Journal Info: | Publisher: American Medical Association Country of Publication: United States NLM ID: 7501160 Publication Model: Print Cited Medium: Internet ISSN: 1538-3598 (Electronic) Linking ISSN: 00987484 NLM ISO Abbreviation: JAMA Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1538-3598 |
|---|---|
| DOI: | 10.1001/jama.2025.20834 |
